Hetero to launch Covid drug Remdesivir under brand name Covifor in India
Hyderabad-based Hetero Labs on Sunday said it had received regulatory
approval to manufacture and market antiviral drug remdesivir for
treating coronavirus patients.
Hetero's generic version of remdesivir will be marketed under the brand
name 'Covifor' in India, said the company after getting approval from
the Drug Controller General of India (DCGI).
“In the light of increasing Covid-19 cases in India, the approval of
Covifor (Remdesivir) can prove to be a game-changer given its positive
clinical outcomes. Backed by strong backward integration capabilities,
we can ensure that the product is immediately made available to patients
across the country," said B Partha Saradhi Reddy, chairman of Hetero Group of Companies.
Comments
Post a Comment